CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug124 Biosensor Wiki 1.00
drug151 COVID-19 RT-PCR Wiki 0.58
drug616 Placebo Wiki 0.10

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D000257 Adenoviridae Infections NIH 0.71

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) in Healthy Adults Aged Above 18 Years

This is a phase II, randomised, double-blinded and placebo-controlled clinical trial in healthy adults above 18 years of age. This clinical trial is designed to evaluate the immunogenicity and safety of Ad5-nCoV which encodes for a full-length spike (S) protein of SARS-CoV-2.

NCT04341389 COVID-19 Biological: Recombinant novel coronavirus vaccine (Adenovirus type 5 vector) Other: Placebo
MeSH:Adenoviridae Infections

Primary Outcomes

Measure: Occurrence of adverse reactions

Time: 0-14 days post vaccination

Measure: Anti SARS-CoV-2 S antibody response(ELISA)

Time: 28 days post vaccination

Measure: Neutralizing antibody response to SARS-CoV-2

Time: 28 days post vaccination

Secondary Outcomes

Measure: Occurrence of adverse events

Time: 0-28 days post vaccination

Measure: Occurrence of serious adverse reaction

Time: 0-6 months post vaccination

Measure: Anti SARS-CoV-2 S antibody response(ELISA)

Time: 14 days, 6 months post vaccination

Measure: Neutralizing antibody response to SARS-CoV-2

Time: 6 months post vaccination

Measure: Neutralizing antibody response to Ad5-vector

Time: 28 days, 6 months post vaccination

No related HPO nodes (Using clinical trials)